HomeCompareONCT vs EPRT

ONCT vs EPRT: Dividend Comparison 2026

ONCT yields 379.79% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCT wins by $7846.52M in total portfolio value
10 years
ONCT
ONCT
● Live price
379.79%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7846.59M
Annual income
$5,169,197,450.71
Full ONCT calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ONCT vs EPRT

📍 ONCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCT
Annual income on $10K today (after 15% tax)
$32,282.57/yr
After 10yr DRIP, annual income (after tax)
$4,393,817,833.10/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ONCT beats the other by $4,393,806,918.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCT + EPRT for your $10,000?

ONCT: 50%EPRT: 50%
100% EPRT50/50100% ONCT
Portfolio after 10yr
$3923.33M
Annual income
$2,584,605,145.71/yr
Blended yield
65.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ONCT
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Price Target
$28.00
+5217.1% upside vs current
Range: $28.00 — $28.00
Altman Z
-28.6
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCT buys
0
EPRT buys
0
No recent congressional trades found for ONCT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCTEPRT
Forward yield379.79%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$7846.59M$63.4K
Annual income after 10y$5,169,197,450.71$12,840.73
Total dividends collected$7596.65M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$28.00$35.50

Year-by-year: ONCT vs EPRT ($10,000, DRIP)

YearONCT PortfolioONCT Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$48,679$37,979.49$11,205$505.18+$37.5KONCT
2$224,874$172,787.13$12,672$682.46+$212.2KONCT
3$986,585$745,969.70$14,490$930.48+$972.1KONCT
4$4,114,314$3,058,668.09$16,786$1,282.69+$4.10MONCT
5$16,323,283$11,920,966.77$19,753$1,791.56+$16.30MONCT
6$61,667,489$44,201,576.55$23,677$2,541.64+$61.64MONCT
7$222,048,216$156,064,002.73$29,008$3,672.99+$222.02MONCT
8$762,773,776$525,182,185.09$36,463$5,425.08+$762.74MONCT
9$2,502,234,339$1,686,066,398.09$47,238$8,221.57+$2502.19MONCT
10$7,846,588,193$5,169,197,450.71$63,385$12,840.73+$7846.52MONCT

ONCT vs EPRT: Complete Analysis 2026

ONCTStock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Full ONCT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ONCT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCT vs SCHDONCT vs JEPIONCT vs OONCT vs KOONCT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.